All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Alex Herrera of City of Hope in Duarte, California, and colleagues, performed a retrospective analysis of allogeneic stem cell transplant outcomes in patients with double-hit (DHL) or double-expressor lymphomas (DEL). This was published in the November 28 online version of Biology of Blood and Marrow Transplantation.
DHL and DEL are aggressive, B-cell lymphomas. DHL is characterized by gene rearrangement of MYC and BLC2 or BCL6. BCL2 chromosome rearrangement is more common, with a rate of 58% to 85% of DHL cases. DEL is described as co-expression of MYC and BCL2. The rearrangement or co-expression causes a rapidly progressive clinical course that is refractory to chemotherapy and leads to poor survival. Earlier work by Herrera showed that outcomes for DEL and DHL after autologous stem cell transplant led to 4-year progression-free survival (PFS) rates of only 48% and 28%, respectively. This multicenter study sought to observe outcomes following allogeneic transplant in these high-risk patients.
This retrospective analysis showed durable responses for allogeneic transplant in DEL and DHL patients. In this very high-risk group, allogeneic transplant should be considered a viable treatment option in the relapsed and refractory setting.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox